尽管生物标志有所改进,但口服硫酸盐未能减缓早期阿尔茨海默氏病患的认知下降速度。 Oral semaglutide failed to slow cognitive decline in early Alzheimer’s patients despite biomarker improvements.

诺沃·诺迪斯克(Novo Nordisk)宣布,口服硫酸盐(Ozempic和Wegovy的活性成分)在涉及3 800多名患有早期阿尔茨海默氏病的成年人的两阶段试验中并没有减缓认知下降的速度,尽管生物标志有所改善。 Novo Nordisk announced that oral semaglutide, the active ingredient in Ozempic and Wegovy, did not slow cognitive decline in two Phase 3 trials involving over 3,800 adults with early Alzheimer’s disease, despite improvements in biomarkers. 该药物安全且耐受良好,但与安慰剂相比,未能达到延缓疾病进展的主要终点. The drug was safe and well-tolerated but failed to meet its primary endpoint of delaying disease progression compared to placebo. 这些试验包括有轻度认知障碍或轻度痴呆症的病人和确诊的阿米亚素阳性病人,试验将不再延长。 The trials, which included patients with mild cognitive impairment or mild dementia and confirmed amyloid positivity, will not be extended. 专家认为,临床效益的缺乏可能源于后期治疗或有限的脑渗透,而研究人员则继续探索药物的生物影响。 Experts suggest the lack of clinical benefit may stem from late-stage treatment or limited brain penetration, while researchers continue to explore the drug’s biological effects. 确定在即将举行的会议上介绍全部结果。 Full results are set for presentation at upcoming conferences.